DGAP-News: Biotest AG
/ Key word(s): Study
23.02.2021 / 07:00
The issuer is solely responsible for the content of this announcement.
Biotest supports clinical study with Pentaglobin(R) in COVID-19 at the University Hospital AKH Vienna
Dreieich, 23 February 2021. In a study arm of the ACOVACT trial, the treatment of patients with severe COVID-19 with Pentaglobin(R) has been started. ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial) is a multicentre, randomised, controlled, open-label platform trial initiated by the University Hospital AKH Vienna to study various antiviral and adjunctive therapies for COVID-19 patients.
In the study arm, investigating immunomodulatory therapies, 20 COVID-19 patients in intensive care with pneumonia and elevated inflammatory markers and with a risk of developing sepsis or acute respiratory failure will be treated with Pentaglobin(R).
“Due to its immunomodulating effect, we believe Pentaglobin(R) offers a promising approach for treating severe courses of COVID-19 disease and we aim to investigate this more in detail in the ACOVACT trial,” emphasises Univ.-Prof. Dr. Roman Ullrich, Senior Consultant Intensive Care Medicine at the University Clinic for Anaesthesia at the Medical University Vienna who is the principal investigator of the sub-study with Pentaglobin(R).
The IgM-enriched immunoglobulin preparation Pentaglobin(R) is an established treatment option for patients with severe bacterial infections. A meta-analysis of patients with sepsis and septic shock demonstrated a significant reduction in mortality and a shorter duration of mechanical ventilation. Pentaglobin(R) has an immunomodulatory effect and could therefore help to positively influence the often excessive immune response in severe courses of COVID-19. In addition, the antibodies in Pentaglobin(R) can bind to a variety of bacteria and their toxins, supporting their destruction by the immune system. Secondary bacterial infections are increasingly being observed in COVID-19 patients with severe courses of the disease. Biotest supports the project within the scope of an academic-industry collaboration (Investigator Initiated Study).
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1170123|
|End of News||DGAP News Service|